Skip to main content
SpringerLink
Log in

EGFR-directed monoclonal antibodies in non-small cell lung cancer

  • Review
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Several monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been evaluated in patients with non-small cell lung cancer (NSCLC). Cetuximab, a chimeric monoclonal antibody, has been studied in combination with first-line chemotherapy in phase II and two phase III trials in patients with advanced NSCLC. The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. Cetuximab added to carboplatin/paclitaxel failed to improve progression-free survival in the BMS099 phase III trial. However, a meta-analysis of four randomized trials confirmed a significant survival benefit for platinum-based chemotherapy plus cetuximab compared to chemotherapy alone. High EGFR expression of tumor cells was then shown to predict the benefit of cetuximab, whereas KRAS mutations and EGFR fluorescent in situ hybridization analysis were without predictive value. Matuzumab and panitumumab have also been studied in phase II trials. Necitumumab, a fully human monoclonal antibody, is currently evaluated in combination with chemotherapy in two phase III trials in patients with advanced NSCLC. Cetuximab is also studied in combination with chemoradiotherapy in patients with locally advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pirker R, Popper H (2007) New concepts in pulmonary oncology. Eur Respir Mon 39:1–22

    Google Scholar 

  2. Pirker R, Filipits M (2009) Targeted therapies in lung cancer. Curr Pharm Des 15:188–206

    Article  PubMed  CAS  Google Scholar 

  3. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S–13S

    PubMed  CAS  Google Scholar 

  4. Pirker R, Minar W, Filipits M (2008) Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. Clin Lung Cancer 9:S109–S115

    Article  PubMed  Google Scholar 

  5. Soria JC, Mok TS, Cappuzzo F, Jänne PA (2012) EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 38:416–430

    Article  PubMed  CAS  Google Scholar 

  6. Pirker R, Filipits M (2011) Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol Hematol 80:1–9

    Article  PubMed  Google Scholar 

  7. Kurai J, Chikumi H, Hashimoto K et al (2007) Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552–1561

    Article  PubMed  CAS  Google Scholar 

  8. Thienelt CD, Bunn PA Jr, Hanna N et al (2005) Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23:8786–8793

    Article  PubMed  Google Scholar 

  9. Robert F, Blumenschein G, Herbst RS et al (2005) Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23:9089–9096

    Article  PubMed  CAS  Google Scholar 

  10. Belani CP, Schreeder MT, Steis RG et al (2008) Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer 113:2512–2517

    Article  PubMed  CAS  Google Scholar 

  11. Rosell R, Robinet G, Szczesna A et al (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362–369

    Article  PubMed  CAS  Google Scholar 

  12. Butts CA, Bodkin D, Middleman EL et al (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25:5777–5784

    Article  PubMed  CAS  Google Scholar 

  13. Herbst RS, Kelly K, Chansky K et al (2010) Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol 28(31):4747–4754. doi:10.1200/JCO.2009.27.9356

    Article  PubMed  CAS  Google Scholar 

  14. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531

    Article  PubMed  CAS  Google Scholar 

  15. Lynch TJ, Patel T, Dreisbach L et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911–917

    Article  PubMed  CAS  Google Scholar 

  16. Thatcher N et al (2009) Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials. WCLC [Abstract] A3.7

  17. Pirker R, Pereira JR, von Pawel J et al (2011) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42

    Article  PubMed  Google Scholar 

  18. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R (2011) First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 12(1):30–37

    Article  PubMed  CAS  Google Scholar 

  19. O'Byrne KJ, Gatzemeier U, Bondarenko I et al (2011) Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 12:795–805

    Article  PubMed  Google Scholar 

  20. Khambata-Ford S, Harbison CT, Hart LL et al (2010) Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918–927

    Article  PubMed  CAS  Google Scholar 

  21. Mack P, Holland W, Redman M et al (2009) KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 27:8022, Abstract

    Article  Google Scholar 

  22. Hirsch FR, Herbst RS, Olsen C et al (2008) Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26:3351–3357

    Article  PubMed  CAS  Google Scholar 

  23. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  PubMed  CAS  Google Scholar 

  24. Govindan R, Bogart J, Wang X et al (2009) Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 27:7505, Abstract

    Google Scholar 

  25. Vanhoefer U, Tewes M, Rojo F et al (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175–184

    Article  PubMed  CAS  Google Scholar 

  26. Kollmannsberger C, Schittenhelm M, Honecker F et al (2006) A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17:1007–1013

    Article  PubMed  CAS  Google Scholar 

  27. Schiller JH, von Pawel J, Schütt P et al (2010) Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 5:1977–1985

    Article  PubMed  Google Scholar 

  28. Foon KA, Yang XD, Weiner LM et al (2004) Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58:984–990

    Article  PubMed  CAS  Google Scholar 

  29. Weiner LM, Belldegrun A, Rowinsky E et al (2005) Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 23:3059, Abstract

    Google Scholar 

Download references

Conflict of interest

Dr. Robert Pirker had received speaker’s fee and honoraria for advisory boards from Astra Zeneca, Eli Lilly, and Merck Serono.

Author information

Authors and Affiliations

  1. Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Robert Pirker

Authors
  1. Robert Pirker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Pirker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pirker, R. EGFR-directed monoclonal antibodies in non-small cell lung cancer. Targ Oncol 8, 47–53 (2013). https://doi.org/10.1007/s11523-012-0244-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-012-0244-7

Keywords

Search

Navigation